Publication Name	World Journal of Gastroenterology
Manuscript ID	31466
Country	United States

Received	2016-11-18 09:21
Peer-Review Started	2016-11-21 16:15
First Decision by Editorial Office Director
Return for Revision	2017-01-20 14:53
Revised	2017-02-04 05:48
Publication Fee Transferred	2017-05-26 08:54
Second Decision by Editor	2017-04-11 15:49
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2017-04-13 11:02
Articles in Press	2017-04-13 11:02
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-06-12 09:25
Publish the Manuscript Online	2017-06-20 12:12

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Research & Experimental Medicine
Manuscript Type	Basic Study
Article Title	Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease
Manuscript Source	Unsolicited Manuscript
All Author List	Latha Paka, David E Smith, Dawoon Jung, Siobhan McCormack, Ping Zhou, Bin Duan, Jing-Song Li, Jiaqi Shi, Yong-Jie Hao, Kai Jiang, Michael Yamin, Itzhak D Goldberg and Prakash Narayan
Funding Agency and Grant Number
Corresponding Author	Latha Paka, PhD, Senior Research Scientist, Department of Research and Development, Angion Biomedica Corp., 51 Charles Lindbergh Blvd, Uniondale, NY 11553, United States. spaka@angion.com
Key Words	High fat diet; Liver; Steatosis; Fibrosis; KCa3.1 channel; Senicapoc; Inflammation
Core Tip	Given the large numbers of people with fatty livers and even relatively indolent steatosis can result in a significant population progressing to non-alcoholic steatohepatitis (NASH), NASH with fibrosis and cirrhosis. We report for the first time that a KCa3.1 channel inhibitor exerts an anti-steatotic effect in the setting of fatty liver disease which can be harnessed for the treatment of liver fibrosis. Second, we are the first to report that Senicapoc, a drug that has been through Phase Ⅲ clinical trials, can be repurposed for the treatment of fatty liver disease and potentially for the treatment of other lipid disorders.
Publish Date	2017-06-20 12:12
Citation	Paka L, Smith DE, Jung D, McCormack S, Zhou P, Duan B, Li JS, Shi J, Hao YJ, Jiang K, Yamin M, Goldberg ID, Narayan P. Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease. World J Gastroenterol 2017; 23(23): 4181-4190
URL	http://www.wjgnet.com/1007-9327/full/v23/i23/4181.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i23.4181

Full Article (PDF)	WJG-23-4181.pdf
Full Article (Word)	WJG-23-4181.doc
Manuscript File	31466-Review.docx
Answering Reviewers	31466-Answering reviewers.pdf
Audio Core Tip	31466-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	31466-Conflict-of-interest statement.pdf
Copyright License Agreement	31466-Copyright assignment.pdf
Institutional Animal Care and Use Committee Approval Form or Document	31466-Institutional animal care and use committee statement.pdf
Peer-review Report	31466-Peer-review(s).pdf
Scientific Misconduct Check	31466-Scientific misconduct check.pdf